How You’ll Make an Impact:
The Director, Clinical Development – EMEAI serves as the senior regional Clinical Development leader and primary clinical liaison for the EMEAI region. This role supports global clinical development programs across primarily pharmaceutical products, with some combination products, spanning multiple ophthalmology indications. This role supports direct study execution in region, serving as a regional touchpoint for investigators and key opinion leaders and is responsible for local study performance (site identification, activation, enrollment, etc.).
What You’ll Do:
- Serve as the primary Clinical representative for the EMEAI region, providing clinical and regional insight to global clinical development programs.
- Develop and maintain strong relationships with KOLs and investigators across EMEAI.
- Support regional study feasibility, startup, and performance in partnership with regional partners.
- Provide regional clinical input into global development strategies, protocols, and study designs.
- Collaborate cross-functionally with Regulatory, Biostats/Data Management, Science/Medical Writing, CMC and Global Clinical Operations.
How You’ll Get There:
- Extensive experience in pharmaceutical clinical development, with exposure to combination products preferred.
- Demonstrated experience engaging with KOLs and investigators in ophthalmology and/or rare diseases across international regions.
- Strong understanding of GCP and global clinical development principles.
- Driven self-starter
- Proactively identifies issues/opportunities and delivers solutions
- Data-driven
- Relationship-focused; builds strong connections across stakeholders
- Scientifically inclined—translates complex concepts into actionable study procedures
- Expert communicator (written and verbal) who builds trust and clarity across teams
- 30% travel
Education
Advanced degree in a scientific, medical, or health-related discipline
(PhD, PharmD, MD, or equivalent preferred).
#GKOSEMEAI #GKOSINTERNATIONAL
Generous. Innovative. Leadership-driven. Family-oriented. Socially responsible.
Founded in 1998, Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
Our mission at Glaukos is to truly transform vision by pioneering novel, dropless therapies that can meaningfully advance the standard of care and improve the lives of patients suffering from chronic, sight-threatening eye diseases.
Innovation is at the core of everything we do, and we are resolute in our commitment to challenge conventional thinking with new treatment alternatives that are supported by real science, robust clinical evidence, and an unrelenting focus on patients.
Our constant pursuit of game-changing technologies that disrupt legacy treatment paradigms is encapsulated in the Glaukos mantra “We’ll Go First,” which articulates our willingness to take chances, our determination to forge new ground, and our commitment to continuous improvement in all that we do.
Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is in Aliso Viejo, California with additional locations in San Clemente, California, and Burlington, Massachusetts.
Glaukos Corporation is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex including sexual orientation and gender identity, national origin, disability, protected Veteran Status, or any other characteristic protected by applicable federal, state, or local law.
All offers of employment are contingent upon the successful completion of a background check, including successfully passing a drug screen, based on the position and local regulations.
